Evolving Industry Partnerships and Investments in Cell and Gene Therapies by Smith, DM et al.
Cell Stem Cell
ForumEvolving Industry Partnerships
and Investments in Cell and Gene TherapiesDevyn M. Smith,1,* Emily J. Culme-Seymour,2 and Chris Mason3,4
1Sigilon Therapeutics, 100 Binney Street, Suite 600, Cambridge, MA 02142, USA
2Gene Therapy, Rare Diseases Unit, R&D, GSK, 980 Great West Road, Brentford, Middlesex, TW8 9GS, UK
3Advanced Centre for Biochemical Engineering, University College London, Bernard Katz building, London, WC1E 6BT, UK
4AVROBIO, One Kendall Square, Bldg 300, #201, Cambridge, MA 02139, USA
*Correspondence: devyn@sigilon.com
https://doi.org/10.1016/j.stem.2018.03.004
Cell and gene therapies hold the promise of providing significant and durable health gains to patients in many
disease states and have recently elicited significant investor and partner interest. We cover the current state
of industry partnerships and investments, highlight what makes a partnership advantageous, and discuss
implications for stem cell therapies.Cell and gene therapies hold the promise
of bringing significant clinical benefits to
patients by directly targeting the underly-
ing cause of disease. Gene therapy drew
large investor interest in the 1990s, but
this vanished following an unexpected
patient death and the occurrence of leu-
kemia within clinical studies in the late
1990s and early 2000s (Rubanyi, 2001).
Cell therapy also generated significant
investor interest in the 1990s, but this like-
wise evaporated after a string of clinical
and commercial failures (such as those
that happened with the companies
Organogenesis and Advanced Tissue
Sciences; Pangarkar et al., 2010). Without
substantial investment, academic labora-
tories nonetheless continued to advance
their research and first-in-human clinical
studies. As a result, significant progress
was made on the underlying science
required to develop a next generation
approach to numerous indications. Large
biopharmaceutical companies’ interest in
this field began to increase in the late
2000s as proof-of-concept clinical data
began to emerge (McKernan et al.,
2010). This initial interest was generally
focused on cell-based therapies, primarily
mesenchymal stem cells (MSCs), but has
rapidly expanded in the last 5 or 6 years.
Today, we see a reemergence of gene
therapy and the evolution of new treat-
ments, such as chimeric antigen receptor
(CAR)-T cell therapies, which have been
fueled by billions of dollars of private and
public capital being invested in new com-
panies. This Forum discusses the current
state of partnering and investment across
the fields of cell and gene therapy. In addi-tion, we highlight advantages of the
different types of partnerships with a
view toward the future.
Overview of Large Company
Investments
There has been an increase in the number
of investments that large biopharmaceuti-
cal companies have made between 2010
and 2016 in advanced therapies (note: 50
transactions were evaluated in this
analysis and tool- and technology-related
investments are excluded; see Table S1).
Nearly every major biopharma company
has made investments, generally through
partnerships with three types of external
parties: (1) early-stage, pre-IPO com-
panies (e.g., Transposagen and Precision
Biosciences); (2) publicly listed advanced
therapy asset and technology companies
(e.g., Spark Therapeutics and Juno Thera-
peutics); and (3) academic institutes that
can receive direct funding (e.g., University
of Pennsylvania and University of Texas).
These large company investments have
included outright acquisition, traditional li-
censes that include the components listed
above, and research agreements. In addi-
tion, the majority of these transactions
were completed in 2014–2016 (Figure 1A).
Traditional partnerships can include
four major components: an upfront
amount of cash, payments for milestones
(e.g., an IND filing or BLA approval), roy-
alties (percentage of sales), and pay-
ments for sales milestones. ‘‘Biobucks’’
is a term used for the aggregate potential
monetary amount of the partnership to the
biotech if all milestones and royalties are
successfully achieved.Cell Stem CeThere have been some interesting
trends in the indication, modality, and
mix of companies that have been involved
in deals over this period. Specifically,
there has been a clear focus on oncology
and rare disease indications, as well as a
marked shift away from MSC-like thera-
pies to other modalities such as CAR-T
cells, gene therapy, and gene editing.
Undoubtedly, there has been much more
deal-making activity direct from global
biopharma in advanced therapies than
seen previously (Figure 1). Each of these
trends will be explored further here.
Trends in Transaction Type
A review of the transactions evaluated in
this analysis has highlighted the shift to a
more collaborative model instead of the
traditional approach to build internally
and/or acquire (Figure 1A). The benefits
of maintaining a collaborative partnering
approach are significant, including a cap-
ital sparing approach that leverages the
links to the founding scientists and their
institutions to help the biopharma learn
how to optimize the development, manu-
facture, and clinical/regulatory aspects of
the partnered assets. There have been
several direct partnerships and collabora-
tions with translationally focused aca-
demic centers (accounting for 12% of
the evaluated transactions), which have
proven to be a key innovation source for
growing existing pipelines. This has
created excitement within academic cir-
cles, where such transactions bring signif-
icant funding and enable translational
expertise to develop. Since these trans-

























































































Figure 1. The Majority of the Public Transactions/Investments Made by Large Pharma Companies for Therapeutics in the Cell and Gene
Therapy Space between 2010 and 2016
(A) Summary of the different transaction types, determined by the nature of the deal.
(B) Summary of the transactions by year by therapeutic area, determined by evaluating the targeted indications and placing them into relevant therapeutic areas.
(C) Summary of the transactions by year by technology type.
(D) Top entities that have performed the most transactions over the period.
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vestigators, these types of partnerships
can on occasion result in decreasing
openness and general unwillingness for
the academic center to consider new col-
laborations. This is negated, however,
when successful partnerships result in
new medicine creation and development,
which can demonstrate the value of the
deal to both parties, and thus allow
expansion in scope of the original partner-
ship itself.
Trends in Indication Focus
As mentioned above, there has been a
clear preference for partnering with
biotech companies in the oncology (e.g.,
leukemia and other hematological malig-
nancies) and rare disease (e.g., hemophil-
ia and lysosomal storage diseases)
spaces, which has been driven by the
positive clinical data generated in these
areas (Figure 1B). The bulk of the recent
oncology-focused collaborations revolve
around biopharma companies accessing
core science and technology based on624 Cell Stem Cell 22, May 3, 2018harnessing the patient’s own immune
system via gene modification to redirect
it to destroy the patient’s tumor cells.
There has been huge success in
numerous clinical studies deploying this
approach, with autologous immune sys-
tem redirection via modifications with
genes encoding for efficacious T cell re-
ceptors (e.g., GSK and Adaptimmune in
2014) and CAR molecules (e.g., Novartis
and the University of Pennsylvania in
2012 and Baxalta/Shire and Precision
Medicine in 2016). These T cell therapy
platforms have demonstrated dramatic
clinical improvements in previously un-
treatable pediatric and adult hematologi-
cal malignancies, albeit with some safety
aspects remaining to be addressed (Ra-
poport et al., 2015; Gill and June, 2015).
One of the earliest partnerships in
oncology was between Novartis and the
University of Pennsylvania in 2012, with
the parties forging a research and
licensing agreement to work together to
commercialize CD19 immunotherapies
for oncology indications. The $20M up-front payment for this collaborative deal
was unprecedented within the cell and
gene therapy community at the time.
This partnership has been successful
given the approval of the first FDA-
approved CAR-T cell therapy, Kymriah,
in 2017 (as outlined in Fortune). One inter-
esting challenge for the oncology space
regarding the T cell-based therapies is
the limited success in solid tumor indica-
tions to date, though significant efforts
have been underway for a while to find
new robust targets for CAR-T cells to effi-
caciously treat such indications (Guo
et al., 2016).
There are many gene therapy deals that
cover multiple therapeutic areas with a
dominance in rare (orphan) diseases
(Figure 1C). The strategy in rare diseases
is predominantly focused on Mendelian-
based orphan diseases, where amutation
in a single gene will give rise to the dis-
ease. Bayer and Dimension Therapeutics
announced a collaboration in 2014 to
develop and commercialize a gene ther-
apy for the treatment of hemophilia A,
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virus (AAV)-based gene therapy platform.
Pfizer and Spark Therapeutics also
announced a collaboration in 2014
focused on developing AAV-based gene
therapy for hemophilia B, which has
recently shown highly promising clinical
trial data (via Spark Therapeutics), and
in 2017, Spark themselves received
approval of the first FDA-approved gene
therapy, Luxturna, an AAV-based gene
therapy for a rare form of inherited vision
loss. Another key collaboration in this field
was the strategic alliance between GSK
and the Telethon Institute for Gene Ther-
apy (TIGET) to develop gene therapy
treatments for rare genetic disorders,
with the first asset from this partnership,
an ex vivo gene therapy indicated for
ADA-SCID, receiving marketing approval
from the European Medicines Agency in
2016, under the brand name Strimvelis
(Touchot and Flume, 2017). Finally, a
recent deal between the University of
Pennsylvania and Biogen (as outlined by
Xconomy Boston), with notable financial
terms involving an upfront payment of
$20M and up to $2B in biobucks, high-
lights the amounts that companies are
willing to spend to access potential
step-change therapies.
Trends in Modality Focus
There has been a clear shift from first-
generation cell therapies (e.g., MSC-like
cells and pluripotent cells) to next genera-
tion approaches such as gene therapy,
CAR-T cells, and gene editing (see
Figure 1D). In the 2014–2016 period, there
was significant activity in CAR-T cells, fol-
lowed by gene therapy, with cell therapy
having a surge in deals in 2016. This surge
in deals over this 3 year period has likely
been driven by the spate of positive clin-
ical data from gene therapy and CAR-T
clinical studies.
Gene editing is widely acknowledged to
have the potential to radically change the
safety proposition regarding gene inser-
tion into patient cells, both ex vivo and
in vivo, as well as the possibility to amelio-
rate a disease entirely, though undoubt-
edly there remain many unknowns yet to
be clarified (Haas et al., 2017). Nonethe-
less, and despite the lack of clinical data
available, many biopharmaceutical com-
panies have solidified deals related to
this technology. Bayer and CRISPR Ther-
apeutics announced a collaboration inDecember 2015 with a joint venture
named Casebia Therapeutics focused
on a gene editing platform using the
CRISPR/Cas9 system. The Cellectis col-
laborations initiated between Pfizer and
Servier in 2014 have focused on devel-
oping allogeneic T cell therapies for
various oncology targets using another
gene editing platform, the TALEN system,
with the goal of engineering T cells defi-
cient in expression of their T cell receptors
(Poirot et al., 2015). In terms of progress
into the clinic, the phase I trial of the Cel-
lectis product is already underway in the
UK for B cell acute lymphoblastic leuke-
mia. For the CRISPR/Cas9 system, it is
likely that 2018 will see the initiation of
the first USA clinical trial involving
CRISPR-mediated gene editing for can-
cer, with another study already underway
in China that treated the first patient in
November 2016 (Cyranoski, 2016).
Trends in Company Mix
Many of the deals evaluated here were
initially made with early-stage pre-IPO
companies who have since become pub-
licly traded (e.g., Spark, Juno, and Intel-
lia). What is unique in this space is the
number of deals that have been signed,
despite the asset not yet being clinic-
ready. This is quite unusual given that
large biopharma companies often prefer
asset deals that already have accompa-
nying clinical data. In terms of geography
of the non-pharma partner, most of the
companies or groups have been USA
based, though Europe is also strongly
represented (e.g., TIGET, uniQure, and
Oxford BioMedica).
The Ideal Partnership Model
There are important considerations when
searching for a potential partner. For
example, a small company will be looking
for a partner to provide the essential cap-
ital required to fund the development of
their therapy, as well as a partner who
can bring development and commercial
expertise to the table. Meanwhile, a larger
company is looking for an asset within a
current strategy/business focus, as well
as scientific expertise in that modality/
asset, and new talent that can bolster ex-
isting skillsets. Given these requirements,
what are important considerations for a
small company searching for a biopharma
partner? These areas would include:
talented scientists and management,complementary indications both clinically
and commercially, and a sound
manufacturing strategy.
A strong, experienced management
team combined with skilled scientists is
important for a small company to not
only successfully close a deal, but also
execute on the deal as well. Companies
that focus on diseases with identified tar-
gets and known mechanisms of action,
combined with a readily identifiable pa-
tient group and clear clinical endpoints
in the specific indication, have proven to
be highly sought after. This has fueled
the interest in the rare disease space,
where monogenic conditions are attrac-
tive indications for gene therapy develop-
ment. A robust manufacturing strategy is
another positive in terms of a deal, partic-
ularly since these new therapies require a
dramatic change in thinking about
manufacturing and supply, due to often
onerous and complex process develop-
ment steps, and unique challenges with
regards to logistics and final administra-
tion. In addition, companies must drive
down the cost of goods of their medicines
to ensure profitability of the final product.
This requires significant resources and an
existing understanding of supply and lo-
gistics, something that a biopharma com-
pany can arguably bring to the table.
New opportunities will continue to be
assessed by biopharma in the standard
way: a combination of top quality science,
a skilled team capitalizing on that science,
and an overall fit in terms of strategy and
capability with the existing portfolio.
Long-term financial viability of the medi-
cines arising from the opportunity are
also one of the key drivers, and the
multi-million-dollar deals in recent years
certainly suggest that the bulk of the large
biopharma companies believe that cell
and gene therapies will provide real value
to patients.
Implications for Stem Cell-Based
Therapeutics
While the focus on ex vivo and in vivo gene
and gene-modified cell therapies de-
velops further, this impacts upon the
stem cell therapy sector, at least in terms
of those looking at stem cells as thera-
pies. Following rapid developments in
the isolation, culture, and differentiation
of various stem cell types in the 1990s
and 2000s, their potential as a viable,
scalable source of therapies seemedCell Stem Cell 22, May 3, 2018 625
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large amounts of money were subse-
quently fed into the sector by public fund-
ing and private investment. This promise
was by no means ignored by big pharma,
many of whom set up key partnerships
with small and medium-sized enterprises
(SMEs) and early-stage developers, as
well as those growing large in-house
research and development offerings
(e.g., Pfizer/Athersys). However, as
some of the key trials designed to show
efficacy did not reach their efficacy end-
points, the concern emerged that stem
cell therapies may not materialize into
the numerous transformational medicines
promised. Next to efficacy, duration of
effect and the ability to be disease-
modifying beyond a temporary response
remains to be seen in the ongoing clinical
trials. This by no means has deterred new
stem cell therapy-focused companies
from commencing important programs
that, if successful, would have tremen-
dous impacts in many diseases. In addi-
tion, the regulatory environment across
the world has shifted to view cell and
gene therapies more favorably as demon-
strated by the USA (21st Century Cures
Act) and Japan (Pharmaceuticals and
Medical Devices Agency, Japan). Sepa-
rate from regulatory changes, there is sig-
nificant need for new reimbursement
approaches to cell therapies. There are
many models being discussed and time
will tell what models become viable.
A Look to the Future
From2010 to 2016, substantial amounts of
money have been invested in cell and gene
therapy, from both the deals being
completed and significant investment by
the public and private sectors (as outlined
by Business Insider). This investment has
in turn enabled a growth in the number
of clinical trials initiated (as outlined by
Cell Trials), which should lead to new
approved therapies. In fact, there are
several potential new therapies involving
CAR-T cells and gene therapy that are
fast approaching submission for FDA
approval, withNovartis’ and Kite Pharma’s626 Cell Stem Cell 22, May 3, 2018CAR-T products and Spark’s AAV gene
therapy product already having been
approved by the FDA in the last few
months. New investment into the field as
a whole has resulted in the formation of
companies focused on delivering the next
generation of therapeutics, with a focus
on areas including new delivery routes
and approaches to managing the host’s
immune system (e.g., Universal Cells and
Sigilon Therapeutics), the engineering of
other cell populations such as tumor- and
marrow-infiltrating lymphocytes, and the
growth of next generation gene therapy
approaches (e.g., novel vector designs
and non-viral technologies) and innovative
bone marrow transplant approaches to
regenerative therapy (e.g., Magenta
Therapeutics). It is an exciting time for
cell and gene therapy—a field whose
time has finally come.
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